Arch Argent Pediatr. 2016 Aug 1;114(4):385-90. doi: 10.5546/aap.2016.385.
Kawasaki disease is an acute self-limiting systemic vasculitis. It is the most common cause of acquired heart disease, with the risk of developing coronary artery aneurysms, myocardial infarction and sudden death. Diagnosis is based on the presence of fever in addition to other clinical criteria. The quarter of the Kawasaki disease patients have "incomplete" presentation. Treatment with intravenous immunoglobulin within ten days of fever onset improves clinical outcomes and reduces the incidence of coronary artery dilation to less than 5%. Non-responders to standard therapy have shown a successful response with the use of corticosteroids and/or biological agents. The long-term management must be delineated according to the degree of coronary involvement in a multidisciplinary manner. To facilitate the pediatrician's diagnosis, treatment and monitoring of Kawasaki disease, a group of experts from the Argentine Society of Pediatrics and the Argentine Society of Cardiology carried out a consensus to develop practical clinical guidelines.
川崎病是一种急性自限性全身性血管炎。它是后天性心脏病最常见的病因，有发生冠状动脉瘤、心肌梗死和猝死的风险。诊断基于发热以及其他临床标准。四分之一的川崎病患者有“不完全”表现。发热开始十天内静脉注射免疫球蛋白治疗可改善临床结果，并将冠状动脉扩张的发生率降低至5%以下。对标准治疗无反应者使用皮质类固醇和/或生物制剂已显示出成功的反应。必须根据冠状动脉受累程度以多学科方式进行长期管理。为便于儿科医生对川崎病进行诊断、治疗和监测，阿根廷儿科学会和阿根廷心脏病学会的一组专家达成共识，制定了实用的临床指南。
